{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:40:47Z","timestamp":1761129647391,"version":"3.40.5"},"reference-count":22,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.mayocp.2019.01.045","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T17:39:31Z","timestamp":1562866771000},"page":"1524-1534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Adjuvant Therapy in High-Risk Renal Cell Cancer: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"94","author":[{"given":"Irbaz B.","family":"Riaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warda","family":"Faridi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Husnain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad Ullah","family":"Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qurat Ul Ain R.","family":"Sipra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farva R.","family":"Gondal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4630-9903","authenticated-orcid":false,"given":"Siddhartha","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9735-6614","authenticated-orcid":false,"given":"Manish","family":"Kohli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.mayocp.2019.01.045_bib1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF00184870","article-title":"Morphological classification of renal cancer","volume":"13","author":"St\u00f6rkel","year":"1995","journal-title":"World J Urol"},{"issue":"5","key":"10.1016\/j.mayocp.2019.01.045_bib2","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"year":"2018","series-title":"Cancer Facts & Figures","key":"10.1016\/j.mayocp.2019.01.045_bib3"},{"issue":"4","key":"10.1016\/j.mayocp.2019.01.045_bib4","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0094-0143(03)00056-9","article-title":"Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease","volume":"30","author":"Janzen","year":"2003","journal-title":"Urol Clin North Am"},{"year":"2017","series-title":"Renal Mass and Localized Renal Cancer: AUA Guideline","author":"American Urological Association (AUA)","key":"10.1016\/j.mayocp.2019.01.045_bib5"},{"issue":"7","key":"10.1016\/j.mayocp.2019.01.045_bib6","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/cncr.11234","article-title":"Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials","volume":"97","author":"Leibovich","year":"2003","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.mayocp.2019.01.045_bib7","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1053\/j.seminoncol.2013.05.004","article-title":"Adjuvant therapy in renal cell carcinoma: past, present, and future","volume":"40","author":"Janowitz","year":"2013","journal-title":"Semin Oncol"},{"issue":"35","key":"10.1016\/j.mayocp.2019.01.045_bib8","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1200\/JCO.2017.73.5324","article-title":"Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma","volume":"35","author":"Motzer","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.mayocp.2019.01.045_bib9","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1056\/NEJMoa1611406","article-title":"Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy","volume":"375","author":"Ravaud","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"10032","key":"10.1016\/j.mayocp.2019.01.045_bib10","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(16)00559-6","article-title":"Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial","volume":"387","author":"Haas","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.mayocp.2019.01.045_bib11","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/annonc\/mdy454","article-title":"Axitinib versus placebo as an adjuvant treatment for renal cell carcinoma: results from the phase III, randomized ATLAS trial","volume":"29","author":"Gross-Goupil","year":"2018","journal-title":"Ann Oncol"},{"year":"2018","series-title":"Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery","key":"10.1016\/j.mayocp.2019.01.045_bib12"},{"issue":"7414","key":"10.1016\/j.mayocp.2019.01.045_bib13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.mayocp.2019.01.045_bib14","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1200\/JCO.2003.02.005","article-title":"Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group\/Intergroup trial","volume":"21","author":"Messing","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2019.01.045_bib15","first-page":"327","article-title":"In\u00a0vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.mayocp.2019.01.045_bib16","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.eururo.2012.01.012","article-title":"Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma","volume":"61","author":"Kroeger","year":"2012","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.mayocp.2019.01.045_bib17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","article-title":"Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis","volume":"15","author":"Ebos","year":"2009","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.mayocp.2019.01.045_bib18","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1148\/radiol.2521081059","article-title":"Does arterial spin-labeling MR imaging\u2013measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?","volume":"251","author":"Schor-Bardach","year":"2009","journal-title":"Radiology"},{"issue":"5","key":"10.1016\/j.mayocp.2019.01.045_bib19","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.eururo.2016.10.023","article-title":"Adjuvant treatment of high-risk renal cell carcinoma: leaving the desert?","volume":"71","author":"Kroeger","year":"2017","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.mayocp.2019.01.045_bib20","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/annonc\/mdx743","article-title":"Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?","volume":"29","author":"Figlin","year":"2018","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.mayocp.2019.01.045_bib21","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1001\/jamaoncol.2017.0076","article-title":"Adjuvant treatment for high-risk clear cell renal cancer: updated results of a high-risk subset of the ASSURE randomized trial","volume":"3","author":"Haas","year":"2017","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2019.01.045_bib22","first-page":"466","article-title":"Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system","volume":"174","author":"Lam","year":"2005","journal-title":"J\u00a0Urol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619619302174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619619302174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T16:22:49Z","timestamp":1565281369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619619302174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0025619619302174"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2019.01.045","relation":{},"ISSN":["0025-6196"],"issn-type":[{"type":"print","value":"0025-6196"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant Therapy in High-Risk Renal Cell Cancer: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2019.01.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}